Please assess the completion status of the following clinical trial:

Trial Title: A First-In-Human Study With a Single Dose UCB7665 in Healthy Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 9.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male and female volunteers of non-childbearing potential who gave their consent to the written informed consent form~* Healthy volunteers in the age between 18 and 64 years old with normal weight as determined by a body mass index (BMI) between 18 and 30 kg/m\^2, with a body weight of at least 50 kg for male subjects or 45 kg for female subjects~* Subjects has blood pressure (BP) and pulse within normal range in a supine position after 5 minutes rest~* Subject has clinical laboratory test results within the reference ranges of the testing laboratory or test results that are outside the specified ranges and that are deemed as clinically non-significant~* Subject's electrocardiogram (ECG) is considered normal or abnormal but clinically non-significant~Exclusion Criteria:~* Subject has had significant blood loss, or has donated blood in excess of 400 mL of blood or blood products within 90 days before Day -2, or plans to donate blood during the clinical study~* Subject has a total Immuneglobulin G \<7 g/L or \>16 g/L at the Screening Visit~* Subject has absolute neutrophil count \<1.5x10\^9/L and/or lymphocyte count \<1.0x10\^9/L~* Subject has known viral hepatitis, has a positive test for Hepatitis B surface antigen or is Hepatitis C virus antibody positive~* Subject tests positive to Human Immunodeficiency Virus (HIV) 1/2 antibodies~* Subject has a past medical history or family history of primary immunodeficiency~* Subject is splenectomized~* Subject has a positive TIGRA (T cell interferon γ release assay) at the Screening Visit. If TIGRA is not available, purified protein derivative (PPD) skin test can be substituted and/or chest x-ray performed within 6 months before the Screening Visit showing no evidence of latent/active Tuberculosis (TB)~* Subject has past (in the last 12 months ) or present substance abuse/dependence or concurrent medical conditions that in the opinion of the investigator could confound clinical study interpretation or affect the subject's ability to fully participate in the clinical study~* Subject has a known hypersensitivity to any components of the Investigational Medicinal Product (IMP)~* Subject has an active infection or has had a serious infection (resulting in hospitalization or requiring parenteral antibiotic treatment) within 6 weeks before the first dose of IMP~* Subject has 12-lead electrocardiogram (ECG) with changes considered to be clinically significant upon medical review~* Subject has renal impairment~* Subject has hepatic impairment~* Subject has corrected serum calcium of \>11.5 mg/dL (\>2.9 mmol/L) or \<8.0 mg/dL (\<2.0 mmol/L) at the Screening Visit~* Subject has active neoplastic disease or history of neoplastic disease within 5 years of entry in the clinical study~* Subject has any other acute or chronic illness which, in the opinion of the investigator or study physician, could pose a threat or harm to the subjects~* Subject has received a vaccination within 6 weeks before the Screening Visit or intends to have a vaccination before Day 43 of the Safety Follow-up Period~* Subject has received any IMP or experimental procedure within 90 days before the first dose of IMP~* Subject requires a treatment other than Paracetamol during the clinical study~* Subject is a vulnerable subject (e.g. subject kept in detention) (Declaration of Helsinki, 1996)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: t

Study Arms:
- UCB7665 Intravenous 1 (Type: EXPERIMENTAL): Single dose calculated based on body weight for 60 minutes intravenous infusion.
- UCB7665 Intravenous 2 (Type: EXPERIMENTAL): Single dose calculated based on body weight for 60 minutes intravenous infusion.
- UCB7665 Intravenous 3 (Type: EXPERIMENTAL): Single dose calculated based on body weight for 60 minutes intravenous infusion.
- UCB7665 Intravenous 4 (Type: EXPERIMENTAL): Single dose calculated based on body weight for 60 minutes intravenous infusion.
- UCB7665 Intravenous 5 (Type: EXPERIMENTAL): Single dose calculated based on body weight for 60 minutes intravenous infusion.
- UCB7665 Subcutaneous 1 (Type: EXPERIMENTAL): Single dose calculated based on body weight for 60 minutes subcutaneous infusion.
- UCB7665 Subcutaneous 2 (Type: EXPERIMENTAL): Single dose calculated based on body weight for 60 minutes subcutaneous infusion.
- Intravenous Placebo (Type: PLACEBO_COMPARATOR): Single dose placebo comparator for each active arm of intravenous infusion.
- Subcutaneous Placebo (Type: PLACEBO_COMPARATOR): Single dose placebo comparator for each active arm of subcutaneous infusion.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete